Article

Intracorneal inlay has potential to correct presbyopia safely

A U.S. FDA clinical trial is now under way to explore the potential of intracorneal inlay technology to correct presbyopia in emmetropic patients.

Key Points

Patients at up to 20 centers nationwide are being recruited to receive the inlay (AcuFocus ACI 7000, AcuFocus Inc.), an approach that seeks to improve near and intermediate vision while preserving distance vision in the same eye. The target enrollment is 400, reported George O. Waring III, MD, FRCS, FRCOphth, here at the American Academy of Ophthalmology annual meeting.

"Because it is thin and flexible, it makes minimal change to the corneal curvature underneath the flap," explained Dr. Waring. "Once it is placed, it can be centered around the corneal light reflex or the pupil and the flap can be put back in place. Its optical function is similar to the effect achieved with the F22 stop on a camera."

International studies

Preliminary results from a multinational study of the corneal inlay show that the device is able to improve near vision without affecting distance vision in patients with emmetropic presbyopia, he said.

Omer Faruk Yilmas, MD, of Istanbul, Turkey, performed the surgery on 39 patients with an average age of 55 years. Before surgery, all were emmetropic with good distance vision and poor near vision. At 12 months' follow-up, the uncorrected distance visual acuity remained the same, on average. The uncorrected near visual acuity had been J6 and gradually improved to J1 and J2.

"There is a learning process with this technology," Dr. Waring said. "It takes the brain of the patient a while to figure out how to use this device, so there is a delay of weeks to months to maximum effect. There is, however, a final stability."

The device was considered extremely safe because no eyes that retained the device lost more than 2 lines of best spectacle-corrected visual acuity. In fact, all the patients who kept the device were spectacle-free except for one. Three patients in Turkey did require the device to be removed, one because of an epithelial defect from herpes and the other two patients because of the loss of some distance vision, he continued.

Preliminary FDA studies

Dr. Waring participated in the early FDA trials of the device with implantation in 10 patients with emmetropic presbyopia and normal corneas. Most patients were very pleased with the visual results of the inlay, with some comparing their vision to that of a 21-year-old, he said.

Besides its potential ability to improve near vision, the corneal inlay can be safely removed. The surgeon only has to lift the flap, remove the inlay, and replace the flap, Dr. Waring said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.